Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats.
The present study aims to evaluate the antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic male Wistar rats. To induce diabetes mellitus, rats were injected with streptozotocin intraperitoneally at a single dose of 40mg/kg. Streptozotocin induced diabetic rats showed significant (P<0.05) increase in the levels of blood glucose, glycosylated haemoglobin and significant (P<0.05) decrease in the levels of plasma insulin, body weight and total haemoglobin. Diabetic rats also showed significant (P<0.05) decrease in the activity of hepatic hexokinase and significant (P<0.05) increase in the activities of glucose-6-phosphatase and fructose-1, 6-bisphosphatase. The pancreatic thiobarbituric acid reactive substances and lipid hydroperoxides were significantly (P<0.05) increased and the activities of pancreatic superoxide dismutase, catalase and glutathione peroxidase were significantly (P<0.05) decreased in diabetic rats. Oral treatment with gallic acid (10 and 20mg/kg) daily for a period of 21days showed significant (P<0.05) protective effects on all the biochemical parameters studied. Histopathology of pancreas confirmed the protective effects of gallic acid in diabetic rats. In vitro study also revealed the potent antioxidant effect of gallic acid. Thus, the study shows the antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic rats. The effect exerted by 20mg/kg body weight of gallic acid was more effective than 10mg/kg body weight of gallic acid.
Punithavathi
Vilapakkam Ranganathan
VR
Department of Biochemistry and Biotechnology, Annamalai University, Annamalai Nagar-608002, Tamil Nadu, India.
Prince
Ponnian Stanely Mainzen
PS
Kumar
Ramesh
R
Selvakumari
Jemmi
J
D000818:Animals; D052160:Benzothiazoles / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016166:Free Radical Scavengers / Q000494:pharmacology* / Q000627:therapeutic use; D005707:Gallic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D013451:Sulfonic Acids / Q000378:metabolism
D052160:Benzothiazoles; D001786:Blood Glucose; D016166:Free Radical Scavengers; D005707:Gallic Acid; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D013451:Sulfonic Acids; C002502:2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid